Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitazoxanide for Mild to Moderate COVID-19 in High Risk Adults
NCT04523090Phase 3Terminated
- Sponsor
- University of Cape Town
- Start
- Aug 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nitazoxanide in coronavirus disease 2019 (COVID-19), sponsored by University of Cape Town. Started Aug 2020; status: terminated.
02
Drugs
nitazoxanide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04523090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523090.